Clinical Chemistry · 2020 · 212 citations · 10 references
Veterinary MedicineInfectious DiseasesMolecular DiagnosticsMolecular VirologyVirologyRespiratory DiseaseRespiratory InfectionsRespiratory Infectious DiseasesSerological DiagnosticsViral DiagnosticsAssayCoronavirus DiagnosticsDiagnostic SensitivityEmergenceSars-cov-2 InfectionSensitivitySevere Acute Respiratory SyndromeSymptom Onset Timing
BACKGROUND: The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a rapid proliferation of serologic assays. However, little is known about their clinical performance. Here, we compared two commercial SARS-CoV-2 IgG assays. METHODS: 103 specimens from 48 patients with PCR-confirmed SARS-CoV-2 infections and 153 control specimens were analyzed using SARS-CoV-2 serologic assays by Abbott and EUROIMMUN (EI). Duration from symptom onset was determined by medical record review. Diagnostic sensitivity, specificity, and concordance were calculated. RESULTS: The Abbott SARS-CoV-2 assay had a diagnostic specificity of 99.4% (95% CI; 96.41-99.98%), and sensitivity of 0.0% (95% CI; 0.00-26.47%) at <3 days post symptom onset, 30.0% (95% CI; 11.89-54.28) at 3-7d, 47.8% (95% CI; 26.82-69.41) at 8-13d and 93.8% (95% CI; 82.80-98.69) at ≥14d. Diagnostic specificity on the EI assay was 94.8% (95% CI; 89.96-97.72) if borderline results were considered positive and 96.7% (95% CI; 92.54-98.93) if borderline results were considered negative. The diagnostic sensitivity was 0.0% (95% CI; 0.00-26.47%) at <3d, 25.0% (95% CI; 8.66-49.10) at 3-7d, 56.5% (95% CI; 34.49-76.81) at 3-7d and 85.4% (95% CI; 72.24-93.93) at ≥14d if borderline results were considered positive. The qualitative concordance between the assays was 0.83 (95% CI; 0.75-0.91). CONCLUSION: The Abbott SARS-CoV-2 assay had fewer false positive and false negative results than the EI assay. However, diagnostic sensitivity was poor in both assays during the first 14 days of symptoms.
10
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell · 2020 · 9.1K citations · Full text
Kelvin Kai‐Wang To, Owen Tak-Yin Tsang, Wai-Shing Leung et al. · The Lancet Infectious Diseases · 2020 · 3.4K citations · Full text
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quanxin Long, Bai-Zhong Liu, Haijun Deng et al. · Nature Medicine · 2020 · 3.1K citations · Full text
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen, Zhaoqin Wang, Fang Zhao et al. · JAMA · 2020 · 2.4K citations · Full text